Impulsivity Domains and Subjective Response
Launched by JESSICA WEAFER · Jun 25, 2023
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how two factors—impulsivity (the tendency to act quickly without thinking) and how people feel after drinking alcohol—affect young adults who might be at risk for Alcohol Use Disorder (AUD). Researchers want to understand these relationships better, as this could help find new ways to prevent and treat AUD in young adults. The trial is currently recruiting participants aged 21 to 25 who have consumed alcohol to a certain level in the past month and drink regularly.
If you or someone you know is interested in participating, it’s important to know that eligible participants must be fluent in English and meet specific drinking habits. However, individuals with serious health issues, certain psychiatric disorders, or those who use specific medications or drugs may not qualify. Participants will take part in various assessments and studies to help researchers gather valuable information. This could lead to important insights for improving treatment options for those struggling with alcohol use.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 21-25 years old
- • Report drinking to an estimated BAC \> .08% at least once in the past 30 days based on responses on the Timeline Followback (TLFB)
- • Report drinking at least twice weekly in the past 30 days based on responses on the TLFB
- • Fluency in English
- Exclusion Criteria:
- • Any serious medical problems (e.g., liver disease, cardiac abnormality, pancreatitis, diabetes, neurological problems, and gastrointestinal disorders)
- • Body weight \< 110 or \> 210 pounds
- • Axis I psychiatric disorders including substance use disorder other than mild or moderate alcohol or mild cannabis use disorder
- • Current alcohol withdrawal or history of medically-assisted detoxification
- • Two positive breath alcohol concentration (BrAC) readings (i.e., \> 0.00%) at an in-person screening appointment or experimental session
- • Positive urine screen for illegal drugs other than cannabis
- • Currently seeking or past-12-month history of inpatient or intensive treatment for addictive behaviors
- • Current psychotropic medication use or receipt of a prescription for these medications in the past 30 days
- • Psychosis or other psychiatric disability
- • Pregnancy, nursing or lack of reliable birth control use for women
- • Report smoking \> 5 cigarettes per day (to avoid acute nicotine effects or withdrawal during experimental sessions)
About Jessica Weafer
Jessica Weafer is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With expertise in orchestrating innovative clinical studies, Jessica fosters collaborations between researchers, healthcare professionals, and regulatory bodies to ensure the integrity and efficacy of trials. Her focus on ethical practices and adherence to regulatory standards underpins a robust framework for developing new therapies. Through meticulous planning and execution, Jessica Weafer is dedicated to contributing valuable insights that will ultimately enhance healthcare solutions and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbus, Ohio, United States
Columbus, Ohio, United States
Boston, Massachusetts, United States
Patients applied
Trial Officials
Jessica Weafer, PhD
Principal Investigator
Ohio State University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported